Infliximab-Induced Lupus in a Patient With Psoriatic Arthritis Who Presented With Cardiac Tamponade: A Case Report

Document Type

Article

Publication Date

3-1-2023

Publication Title

Cureus

Abstract

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory condition, and the proinflammatory cytokine tumor necrosis factor-α (TNF-α) plays a major pathogenic role in the development and progression of PsA. Anti-TNF-α therapies, such as the monoclonal antibody infliximab, are used to treat patients whose PsA has not responded favorably to conventional anti-rheumatic drugs. However, exposure to anti-TNF-α therapeutics can lead to drug-induced lupus erythematosus (DILE), which may rarely be accompanied by cardiac manifestations. Here, we describe a rare case of drug-induced lupus erythematosus secondary to infliximab therapy for PsA and psoriasis in a patient who presented with life-threatening acute pericarditis and cardiac tamponade. Newly developed skin rashes, newly elevated autoimmune indicators, and punch biopsy results indicating subacute cutaneous lupus collectively supported a DILE diagnosis within the context of infliximab use. Pericardiocentesis, colchicine, and corticosteroids alleviated symptoms, and infliximab was replaced with alternate therapy. This case highlights the importance of early recognition of the possible serious and uncommon adverse reactions from infliximab therapy. Prompt initiation of appropriate treatment and discontinuation of the offending agent are critical in cases of drug-induced lupus erythematosus, particularly when rare cardiac complications occur.

PubMed ID

37090269

Volume

15

Issue

3

First Page

36424

Last Page

36424

Find It @ Sladen

Share

COinS